Bruker Daltonics Introduces New MALDI Molecular Imager(TM) for In-Vitro Imaging of Protein Biomarkers in Tissue Sections and Cell Clusters.

BILLERICA, Mass. -- Bruker Daltonics today announces its novel MALDI Molecular Imager(TM), a system for in-vitro imaging of peptide and protein biomarker distributions in tissue sections and cell clusters, for example from tumor regions. The MALDI Molecular Imager addresses the need for high-sensitivity imaging of the spatial distribution of protein biomarkers in biological, pathology and other clinical research (for research use only).

The MALDI Molecular Imager uses an easy-to-use autoFlex(TM) MALDI-TOF mass spectrometer equipped with proprietary smartbeam(TM) laser technology for high-throughput MALDI Imaging. The MALDI Molecular Imager also incorporates powerful flexImaging(TM) visualization and image processing software, and further expands Bruker Daltonics' leading CLINPROT(TM) product line for clinical proteomics and protein biomarker analysis.

The novel and unique MALDI Molecular Imager can be applied whenever tissue sections are used to evaluate cellular histology and to monitor the spatial distribution of biomarkers, e.g. in pathology, morphology, oncology or neurology, and many other clinical research fields. In addition, the MALDI Molecular Imager can be of great value in pharmacology, for example for peptide and protein tissue characterization in transgenic animal models, as well as in basic biological research.

Prof. Richard M. Caprioli, Director, Mass Spectrometry Research Center at the Vanderbilt University Medical Center (Nashville, TN) and first customer of the MALDI Molecular Imager, commented: "Biomarker discovery will benefit enormously from the direct analysis of tissue sections by MALDI-MS. Gaining knowledge about the spatial localization of proteins and compounds in tissue will also provide invaluable knowledge to drug candidate research and chemical compound monitoring in animal and plant tissue."

Dr. Isabelle Fournier, Director of MALDI Imaging in the Neuroimmunology Laboratory of Prof. Michel Salzet at the University of Lille (France), pointed out: "The MALDI Molecular Imager is an important tool for histological research projects. In comparison to immuno-histochemical techniques, it is of special interest that there is neither a need for labeling of biomarkers, nor for the use of antibodies. Moreover, direct profiling of cancer regions identified in tissue biopsies in many cases allows for a sub-typing of tumors, thus giving clinicians additional information for diagnosis and therapy decisions."

Frank Laukien, Ph.D., President and CEO of Bruker Daltonics, stated: "The dedicated MALDI Molecular Imager for in-vitro protein biomarker imaging is a powerful new tool for molecular imaging. We believe that our proprietary smartbeam technology and advanced flexImaging software make this a user-friendly system for many clinical research and biological laboratories that typically would not use mass spectrometry. Together with our collaborators, we are looking forward to bringing this exciting new molecular imaging modality to new customer groups who can benefit from its unique capabilities."

Pittcon 2006, the 57th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, will be held March 13-16 in Orlando, Florida in the Orange County Convention Center. The MALDI Molecular Imager will be exhibited at the Bruker booth #3155.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.